Phagenesis Welcomes Chad Hoskins as CEO
Phagenesis, a pioneering company in the field of neurostimulation therapies, has announced a major leadership transition with the appointment of Chad Hoskins as Chief Executive Officer. This change comes on the heels of the company’s recent successes, including securing $42 million in Series D funding aimed at expanding the reach and impact of their innovative product, Phagenyx®.
New Leadership to Drive Growth
Chad Hoskins brings over twenty years of experience in the medical technology industry, particularly in scaling innovative therapies. His prior role as CEO of Axon Therapies involved developing novel technologies for heart failure treatment, which complements his extensive expertise in commercialization and strategic planning. Mr. Hoskins is set to guide Phagenesis into its next growth phase, concentrating on increasing the adoption of Phagenyx® in both the US and European markets.
The Significance of Phagenyx®
Phagenyx® is a groundbreaking therapy designed to assist patients who experience severe swallowing difficulties, known as dysphagia. This innovative treatment employs pharyngeal electrical stimulation to restore swallowing function, greatly improving the quality of life for patients affected by conditions such as stroke. With millions of people around the globe facing challenges with swallowing, the demand for effective solutions like Phagenyx® is critical.
Plans for Strategic Expansion
Phagenesis is dedicated to increasing the availability of Phagenyx® not only in the US but also on an international scale. The recent funding will primarily support their commercialization efforts, as they strive to connect with healthcare providers and patients who could benefit from this innovative treatment. As the company expands, they are also looking to collaborate with clinicians to significantly improve patient outcomes.
Expertise in Healthcare Innovation
Mr. Hoskins’s understanding of enhancing patient care is bolstered by his previous roles at Outset Medical and Abbott. His educational background in economics, public health, and business administration from esteemed institutions equips him to navigate the complexities of healthcare delivery effectively. This diverse experience provides him with the skills necessary to steer the future direction of Phagenesis.
Understanding Dysphagia and Its Consequences
Dysphagia, or difficulty in swallowing, can severely affect quality of life and pose significant health risks for those affected. It may arise from various conditions, including damage to the central nervous system. Phagenesis aims to address these risks through Phagenyx®, providing urgent non-surgical solutions that can help reduce hospital stays and healthcare costs associated with managing dysphagia.
Company Overview
Founded in 2007, Phagenesis is recognized for its commitment to advancing medical technology solutions that revolutionize the treatment of dysphagia. The ongoing support from leading investors reflects confidence in Phagenesis's vision and the promising future of Phagenyx®. Under Mr. Hoskins's leadership, the company aims to enhance the treatment options available to patients around the world.
Frequently Asked Questions
What is Phagenyx®?
Phagenyx® is a unique therapy that utilizes pharyngeal electrical stimulation to help restore swallowing control in patients with severe dysphagia.
Who is Chad Hoskins?
Chad Hoskins is the newly appointed CEO of Phagenesis, bringing extensive experience in commercializing medical technologies.
What are the goals of Phagenesis with the new funding?
The funding is primarily aimed at enhancing the commercialization efforts of Phagenyx® in the US and Europe, helping more patients access this innovative therapy.
Why is treating dysphagia important?
Treating dysphagia is crucial as it dramatically affects the quality of life, nutrition, and overall health of affected individuals, with risks of serious complications.
How will Chad Hoskins impact the company?
With his strong background in MedTech and a focus on patient outcomes, Mr. Hoskins is expected to drive Phagenesis toward significant growth and innovation in dysphagia treatments.
